United States: Safety Of Both Devices And Drugs Need To Be Better Tracked, FDA Hears From Oversight Bodies

FDA lacks the appropriate data to effectively conduct postmarket surveillance and safety tracking activities, according to two reports released earlier this month. First, Senator Patty Murray's Health, Education, Labor, and Pensions (HELP) Committee staff reported on systemic failures in FDA's postmarket surveillance of medical devices, relating to the lack of information being received by the Agency on device changes and adverse events. Then on January 14, the Government Accountability Office (GAO) released a report finding that FDA lacks timely, accurate, and accessible data to effectively track postmarket safety issues for prescription drugs.

FDA needs to move beyond a "passive postmarket surveillance system" for devices.

Although the Senate HELP Committee report focused on the superbug outbreaks linked to closed-channel duodenoscopes, the authors saw FDA's inability to quickly detect and react to the safety issues presented by those devices as an example of the Agency's need for a more active postmarket safety system to oversee all medical devices.

With slow and incomplete reporting from manufacturers as well as hospitals to alert FDA to medical device safety issues, and the lack of connected data when multiple reports are filed on similar devices, FDA's "passive postmarket surveillance system" failed to timely alert the public and address patient safety issues posed by duodenoscopes on the market. Even after providers linked infections to the devices and manufacturers learned that there were issues with disinfecting the scopes, the reporting among hospitals, manufacturers and FDA was slow, incomplete and informal. Further, when FDA started looking into the safety risks associates with these scopes, it did not immediately alert the public or hospitals that it was investigating a potential issue, because it had not clearly linked the infections to the devices or ruled out more innocuous mishandling issues.

Senator Murray's staff has recommended a number of steps to strengthen FDA's postmarket device surveillance system. Some of the recommendations include:

  • Require unique device identifiers (UDIs) on insurance claims
  • Fund a National Medical Device Evaluation System for FDA to actively monitor medical devices
  • Update FDA guidance for obtaining 510(k) clearance for modified medical devices
  • Make medical device adverse event reporting a Medicare Condition of Participation

The report also suggests that FDA quickly implement its new draft guidance to notify health care providers of patient safety issues that may be posed by a medical device. But these proposed guidelines on "emerging signals" of a device safety issue have generated considerable controversy among stakeholders and fears that device manufacturers will be sued for perceived product defects at a much earlier stage in a safety investigation, so it remains to be seen how the Agency will address those criticisms while also responding to the serious patient safety concerns highlighted by the HELP Committee report.

FDA lacks data to effectively track postmarket safety issues for drugs.

In addition to its device woes, FDA was blasted by the GAO for gaps in the Agency's drug safety tracking system and requirements for postmarket studies, which are meant to help FDA ensure the continued safety of approved prescription drugs. These postmarket safety data-tracking issues are of greater concern to the GAO in light of FDA's increasing use of accelerated pathways to drug approval. The speedier processes typically involve fewer clinical trials before approval, so FDA often depends on additional postmarket studies to assure the drugs' continued safety.

GAO found that FDA's data on tracked safety issues was often incomplete and inaccurate, with delays in data entry by Agency personnel. In response, FDA officials "acknowledged that staff were not following [the Center for Drugs's] policies and procedures for tracking and documenting potential safety issues, but...given the high workload of its review staff it had prioritized identifying, assessing, and addressing potential safety issues over administrative tracking."

In addition, after the data are entered, they are not stored in a way that it can be easily accessed and analyzed for safety trends, or in a way that makes it possible to efficiently confirm the status of a required postmarket study, GAO reported. These data access issues have also delayed the FDA's statutorily required reporting to the public regarding potential safety concerns related to approved drugs.

The GAO pointed out that other agencies have found problems with FDA's monitoring of prescription drug postmarket studies in the past. The HHS Office of Inspector General and GAO each concluded that FDA had failed to effectively monitor postmarket studies in 2006 and 2009, respectively. And in 2008, a contractor brought in to address the "backlog" of postmarket studies found over 500 final reports that were awaiting review by FDA, including some for drugs that had received accelerated approval and needed postapproval studies to confirm their safety and effectiveness.

HHS acknowledged FDA's troubles in tracking these types of postmarket data and commented to GAO that FDA is moving to address its internal data challenges. But the Department, FDA's parent organization, also noted that there are other methods by which FDA tracks and monitors safety issues, in light of its limited resources. We will continue to report on any legislative or other fallout from these two recent high-profile reprimands of the Agency's postmarket safety efforts and systems for drugs and devices.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Rachel Irving Pitts
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Akin Gump Strauss Hauer & Feld LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Akin Gump Strauss Hauer & Feld LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions